Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | PARP inhibitors for the treatment of metastic castration-resistant prostate cancer

Simon J. Crabb, PhD, MBBS, Southampton Experimental Cancer Medicine Centre, Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK, discusses trials presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 investigating the use of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC). Two trials explored the combination of abiraterone with either olaparib or niraparib. The trial investigating olaparib demonstrated positive results for both patients with alteration in genes associated with DNA repair and those who did not have those alterations. In the trial investigating niraparib, patients without DNA repair gene alterations did not appear to benefit, however the results were positive for those with DNA repair gene alterations. Further analysis of these trials will be required to decipher the role of treatment with PARPi in mCRPC. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.